Mizuho dismisses Axsome short report after management call
PremiumThe FlyMizuho dismisses Axsome short report after management call
1M ago
Citi disagrees with Axsome short report, says buy on weakness
PremiumThe Fly
Citi disagrees with Axsome short report, says buy on weakness
1M ago
Axsome weakness on short report a buying opportunity, says Guggenheim
PremiumThe Fly
Axsome weakness on short report a buying opportunity, says Guggenheim
1M ago
FDA to Decide on MDMA Therapy for PTSD
PremiumMarket NewsFDA to Decide on MDMA Therapy for PTSD
2M ago
Axsome Therapeutics joins American Migraine Foundation
PremiumThe Fly
Axsome Therapeutics joins American Migraine Foundation
2M ago
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
PremiumPress Releases
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
2M ago
Axsome Therapeutics price target raised to $112 from $108 at Baird
PremiumThe FlyAxsome Therapeutics price target raised to $112 from $108 at Baird
3M ago
Axsome Therapeutics price target lowered to $125 from $127 at Citi
PremiumThe Fly
Axsome Therapeutics price target lowered to $125 from $127 at Citi
3M ago
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
PremiumPress Releases
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100